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Backgroud: While serum levels of hyarulonic acid (sHA) is known to be useful for a burden of disease biomarker in
knee OA, it is far from practical. The reference intervals must be established for biomarkers to be useful for clinical
interpretation. The aim of this study was to establish the reference intervals of sHA corresponding to the
radiographic severity of knee OA for elucidating whether sHA can be useful as a burden of disease marker for
individual patient with knee OA.
Methods: 372 women with Kellgren & Lawrence grade (K/L) 1 through 4 painful knee OA were enrolled in this
study. The patients included 54 with K/L 1, 96 with K/L 2, 97 with K/L 3, and 118 with K/L 4. Serum samples were
obtained from all subjects on the day that radiographs taken. A HA binding protein based latex agglutination assay
that employed an ELISA format was used to measure sHA. Age and BMI adjusted one way ANOVA was used to set
the reference intervals of sHA.
Results: The reference intervals for sHA corresponding to the patients with K/L 4 (49.6 – 66.5 ng/ml) was
established without any overlap against to those with K/L 1, 2 and 3, while those with K/L 1, 2 and 3 showed
considerable overlap.
Conclusions: These results indicate that sHA can be available as a burden of disease marker for the individuals with
severe knee OA (K/L 4), while it is not for those with primary to moderate knee OA (K/L 1–3).
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Osteoarthritis (OA) Biomarkers Network, which was
funded by National Institute of Health (NIH) and deve-
loped as a partnership with Osteoarthritis Research Society
International (OARSI) and the Arthritis Foundation, pro-
posed the BIPEDS biomarker classification (Burden of
disease, Investigative, Prognostic, Efficacy of intervention,
Diagnosis of the Disease and Safety of interventions) which
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reproduction in any medium, provided the oruse in OA investigations [1,2]. Burden of disease markers
assess the severity of disease within a particular joint among
individuals with OA typically at a single point in time. Stu-
dies of burden of disease markers require comparison with
one or more gold standard methods, such as radiography,
of determining disease severity [3].
The serum level of hyaluronic acid (sHA) is a potential
biomarker for the establishment of a proper management
system in knee OA. Although sHA has been reported to be
a useful burden of disease marker in OA [4-7], it is still far
from being practical.
The reference intervals for a biomarker must be esta-
blished before the marker can be adequate and useful for
clinical interpretation. The International Federation of
Clinical Chemistry and Laboratory Medicine (IFCC) andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Correlation between the sHA levels and age of the
patients. ln-sHA; logarithmically transformed sHA. n=372.
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defined reference intervals as the interval between two
reference limits. In most cases, reference intervals are
designated as the interval between and including two num-
bers, an upper and lower reference limit, which are esti-
mated to enclose a specified percentage (usually 95%) of
the values for a population from which the reference sub-
jects are drawn [8].
The purpose of this study was to establish the reference
intervals of sHA corresponding to the radiographic severity
of knee OA in order to allow sHA to become a more prac-
tical biomarker in knee OA.
Methods
This prospective cohort study protocol was approved by
the institutional review board of Juntendo University and
conducted in accordance with the Declaration of Helsinki.
All patients provided their written informed consent before
enrollment in this trial. Three-hundred seventy-six women
ranging in age from 48 to 86 years (mean 69.1) with knee
pain were recruited. Patients with knee pain complained
pain in the medial femorotibial compartment of the studied
knee on most days of the month prior to examination and
removal of body fluids. None of the patients had expe-
rienced any traumatic episodes during this period. They
fulfilled the criteria of knee OA of the medial femorotibial
joint as defined by the American College of Rheumatology
(ACR) criteria [9]. As several other factors, such as
impaired renal, hepatic function and corticosteroid usage,
affect serum HA levels, patients who had these diseases
were excluded. Standing, extended and antero-posterior
view, and lateral and skyline view radiographs were taken at
the first visit. The staging of knee OA based on radio-
graphic examination was assessed using Kellegren and
Laurence (K/L) grading. The patients included 54 with K/L
grade 1, 96 with K/L grade 2, 97 with K/L grade 3, and 118
with K/L grade 4 based on the weight-bearing antero-
posterior radiographs.
Serum samples were obtained from all subjects on the
day that radiographs taken. As there is a diurnal variation
in HA levels [10,11], fasting blood samples were collected
at late morning-early afternoon for serum analyses. The
serum samples were stored at -80°C until analysis. sHA was
measured using an HA binding protein based latex agglu-
tination assay (Chugai Diagnostics, Tokyo, Japan) that
employed an ELISA format and the intra-assay and inter-
assay variation were less than 5%.
The analyses were performed using SPSS ver.17 (SPSS
Inc., Chicago, IL). The normality of the distribution of each
group was tested by Kolmogorov-Smirnoc statistics. A
correlation analysis was conducted by Spearman’s cor-
relation coefficient. Parametric comparisons were necessary
for the age and body mass index (BMI) adjusted one way
analysis of variance (ANOVA). However, as sHA levels ofthe patients did not show normal distribution, they were
logarithmically transformed (ln-sHA) and the age and BMI
adjusted one way ANOVA was conducted. Significant
differences were evaluated if ANOVA was significant. The
significance of individual differences was evaluated using
the Bonferroni t method. A p-value of less than 0.05 was
considered to be statistically significant.
Results
The age of the patients was significantly increased depend-
ing upon the progression of the disease (K/L grades)
(r=0.46, Figure 1), as reported previously [7]. The BMI of
the patients with either K/L grade 1 or 2 were significantly
different from those with K/L grade 3 and 4, respectively.
The ln-sHA levels of the subjects with K/L grade 4 were
significantly increased in comparison to those with K/L
grade 1, 2 and 3, respectively (Table 1). On the other hand,
no significant difference of the ln-sHA levels were observed
between the subjects with K/L grade 3 and those with K/L
grade 1 and 2 (Table 1). There were no significant dif-
ferences of the ln-sHA levels between the subjects with K/L
grade 1 and grade 2 (Table 1).
The means and 95% confidence interval (CI) of ln-sHA
were reversed into constant sHA and the age and BMI
adjusted reference intervals for sHA corresponding to the
patients with K/L grade 1 to 4 were calculated (Table 2).
The reference intervals for sHA corresponding to the
patients with K/L grade 1, 2 and 3 overlapped considerably.
However, the reference interval of sHA corresponding to
the patients with K/L grade 4 did not show any overlap
between those with any other grades (Table 2).
Table 1 Logarithmically transformed sHA (lnHA) levels of female patients with knee OA corresponding to the K/L
grade
K/L 1 2 3 4 p for trend
LnHA 3.50 (0.11, 3.28-3.72) 3.55 (0.08, 3.39-3.71) 3.74 (0.08, 3.58-3.89) 4.05 (0.08, 3.90-4.20) <0.001
* p=1.00 (−0.41 to 0.30) * p=0.47 (−0.60 to 0.12) * p<0.001 (−0.92 to −0.19)
¶p=0.60 (−0.49 to 0.11) ¶p<0.001 (−0.80 to −0.20)
† p<0.05 (−0.60 to −0.03)
All analyses were adjusted for age and body mass index (BMI). Covariates appearing in the model are evaluated at the following values; age = 69.1, BMI = 24.5. A
p value less than 0.05 was considered to be significant. Data indicates mean (SD, 95%CI) and p (95%CI for differences). K/L: Kellegren and Laurence grade.
*: vs. K/L 1, ¶: vs. K/L 2, †: vs. K/L 3.
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No biomarkers have so far been established as accepted
tools for characterizing the status of OA [12]. This is par-
ticularly due to the fact that there are no biomarkers in OA
that can characterize the disease state in an individual
patient [3,13]. In addition, the burden of disease markers
can be used only for clinical studies because individual
values obtained in groups of patients with different degrees
of OA burden overlap considerably [14]. A reexamination
of the approach for reporting biomarker results was
proposed to overcome this problem [12], and this study
was conducted to determine whether sHA levels could be
employed as a burden of disease marker for individual
patients by estimating the reference intervals of sHA levels
corresponding to the radiographic severity of knee OA.
The results revealed that the reference intervals of sHA in
patients with severe knee OA (K/L grade 4) can be esti-
mated without overlap, while those of the patients with
primary to moderate OA (K/L grade 1 to 3) overlapped,
considerably. These findings indicate that sHA can be avail-
able as a burden of disease marker for severe (K/L grade 4)
knee OA patients and cannot for primary to moderate (K/L
grade 1, 2, and 3) knee OA patients.
A measured or observed laboratory test, such as bio-
marker, are established when a person (usually a patient) is
compared with a reference interval for the purpose of
making a medical diagnosis, therapeutic management deci-
sion, or other physiological assessment. The interpretation
of clinical laboratory data is, therefore, a comparative deci-
sion-making process. This decision making process requires
reliable reference intervals for the biomarkers [8]. There-
fore, the establishment of the reference intervals for sHA
may be useful to predict the prognosis of the disease in an




Reference interval 26.5 - 41.1
Data indicates mean (SD). All analyses were adjusted for age and body mass index
age = 69.1, BMI = 24.5. K/L: Kellegren Laurence grade.biomarker that can predict the prognosis of the disease
[15,16], although further study is necessary.
The burden of disease biomarkers indicates the extent or
severity of disease, and therefore such biomarkers can be
considered to be useful tools for the staging of the disease
[13]. The sHA level has been reported to be a biomarker of
radiographic knee OA [7]. In general, the severity of OA
increases with age, and the sHA level was increased with
age in our study (Figure 1). It is impossible to exclude the
possibility that an overlap of the reference intervals for the
sHA levels corresponding to the patients with K/L grade 1,
2 and 3 may be due to the influence of the extent of the
disease in other joints [2]. However, even though the level
in patients with K/L grade 4 must be affected by the extent
of the disease in other joints, no overlap was shown for the
reference interval of the sHA level corresponding to the
patients with K/L grade 4. The sHA level has been reported
to be a biomarker not only of the burden of disease, but
also as a marker of disease progression [16]. Therefore, the
result of this study could be meaningful, as we were able to
identify the patients with progressive OA using the sHA
level, in addition to examining the radiographic severity of
OA because we cannot distinguish the patients with
progressive OA from those without using solely radiog-
raphy [3,5]. For example, the sHA, in addition to the ra-
diography, may be helpful to identify patients with
progressive OA for inclusion into future clinical trials of
DMORDs.
This current study had some limitations. The study
included only Japanese female patients in the analyses.
Therefore, the findings cannot be generalized to other eth-
nic groups and male patients. Although sHA levels were
affected by total body burden of disease [17], there was no




29.7 - 40.8 36.0 - 48.9 49.6 - 66.5
(BMI). Covariates appearing in the model are evaluated at the following values;
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the systemic levels of biomarkers cannot be addressed.
Conclusions
In conclusion, this study revealed the potential of sHA as a
burden of disease biomarker for the evaluation of individual
patient with severe knee OA (K/L grade 4) and, simultan-
eously, revealed the limitation of sHA as a burden of
disease biomarker for the evaluation of individual patient
with primary to moderate knee OA (K/L grade 1, 2, and 3).
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